Recce Completes Capital Raising of $27.95m
Filed with ASX · · 3 pages · English
sophisticated and professional investors participating in the offer. Recce Pharmaceuticals Chief Executive Officer James Graham said, “We greatly appreciate the support shown by both our existing investors and new institutional investors. Their financial support comes at a transformative time for Recce as we prepare updating the market as our pivotal trials progress in the coming months.” At $1.30
Recce Pharmaceuticals Ltd. on 6ix
Earlier from Recce Pharmaceuticals
- R327 Phase I Study - Australias CMAX Clinical Facility
- Positive & Concentration-Dependent Efficacy Against COVID-19
- Recce Pharmaceuticals Receives Innovation Connections Grant
- Recce Pharmaceuticals Appoints James Graham as CEO
- Positive Oral Data on New RECCE 435 Against H. pylori
Later from Recce Pharmaceuticals
- Murdoch Childrens Research Institute, R435 Against H.Pylori
- HREC Approval to Start Phase I/II Burns Wound Study
- Encouraging Results Against SARS-CoV-2 Virus
- Anti-Viral Patent Granted in Japan for RECCE Anti-Infectives
- Recce Awarded AusIndustry Advanced Overseas (R&D) Finding
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals